Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. - Wikidata - awgldk - TriplyDB

Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy.

Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy.

http://www.wikidata.org/entity/Q36462641

about

Cardiac toxicity of trastuzumab in elderly patients with breast cancer Multimodality Imaging in Cardiooncology Evaluation and management of patients with heart disease and cancer: cardio-oncology Strain imaging to detect cancer therapeutics-related cardiac dysfunction: are we there yet?Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction Noninvasive diagnosis of chemotherapy related cardiotoxicity Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies.Review of Journal of Cardiovascular Magnetic Resonance 2009 Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.Nuclear imaging in detection and monitoring of cardiotoxicity.Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic r An update on cardio-oncology.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.Risk factors for anthracycline-associated cardiotoxicity.Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance.Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.Biological drugs: classic adverse effects and new clinical evidences.Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.Cardiac toxicity of anticancer agents.Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively.Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.Cardiotoxicity due to chemotherapy: role of cardiac imaging.Heart failure and chemotherapeutic agents.Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.Detection of late radiation damage on left atrial fibrosis using cardiac late gadolinium enhancement magnetic resonance imaging.Comprehensive review on cardio-oncology: Role of multimodality imaging.Cardiac MRI: a Translational Imaging Tool for Characterizing Anthracycline-Induced Myocardial Remodeling.Role of Imaging in Cardio-Oncology.Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy.Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.Utility of prechemotherapy echocardiographical assessment of cardiac abnormalities.The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy.Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.

P2860

Q26741182-D7226D14-4A96-46AF-8C12-95E524D230C8 Q26795452-4DCDEA8D-0B1C-4E0B-A7F0-D9B5C97343DD Q26998273-FA1A6523-827E-4628-9015-EE3DF4850ECC Q30385954-4FC33997-0440-4196-970B-9262C6DB002D Q30427656-B7DD08D4-01DD-40E1-B40F-456BC3E9103B Q30446453-4E938261-4E7E-4A7D-A36B-C38CDAA6A3AE Q30461444-AAFCE4CE-8381-492A-AA9B-1CD88C889412 Q30463822-3E488195-1635-41CA-AAA0-7A3E18C05F03 Q30484444-29060CC7-A10D-4BCB-8589-0EE8028C2B5A Q33565936-DBCA5A37-6965-484F-B67D-301B755B4093 Q33595716-8401B7F3-EF9A-47C1-9688-0427B494AEE2 Q33942611-536EC676-A0C8-48BE-8DA5-ACD933A17D95 Q34560383-B9650750-EC33-4FF4-8AA5-B0C3A4733C94 Q34650059-AA107431-8D45-4D63-847F-D6258E63E78F Q35562745-EDB2F38E-DF2B-4422-A714-14B5D910D96B Q35880224-4728DCC5-E90D-4F7A-9517-7369EC512DA2 Q36451899-A9080431-12BF-4973-AD98-07B020F63DCD Q36921775-F2A235F6-0956-48ED-94DF-682FAD0F341B Q37248274-4756D417-82CF-4E2B-99B3-DD68AB04A29E Q37311943-13CE9CD9-7F24-4339-9A9C-38D3701CB062 Q38015746-10224EC0-9E60-46F2-ADC1-6901BCF85C7D Q38042295-F4F4F879-AE36-4CEE-8289-102CBEC5CA49 Q38091377-D1E4EBB2-C080-46C9-859B-D5B245F51442 Q38097736-E56C4175-A066-4CE5-A271-DAD5229BB447 Q38222800-BC001FD1-1D1E-4CF6-BAEF-0BEB0AF82D58 Q38343043-E2748C1E-AA97-482D-B1DE-BE19E4B4966A Q38559133-A012E82C-0C3A-430C-8CAB-950E8E5A209F Q38559474-8F50EDC2-ED15-4081-A2DE-1EBD1B92FED3 Q38663202-755B9D7A-2868-48DC-9B4F-EC22B12F09E6 Q38844387-FB643FF1-B40F-48B8-8303-FB38C7D69184 Q38862688-4D81DA3A-FB3C-49D5-B1E1-8BE71C04C63E Q39285218-AE63B38C-F2B8-4C21-818B-347CB92A4447 Q51367703-A7F4A9B6-05C6-4B30-B07A-FFA436108F18 Q51368192-AAF82A13-5E88-4E5D-ADA6-1FA61FD369F6 Q51530456-E298CEAB-2E4E-4487-89B2-4BA5E0DAA037 Q52982588-C4ED65A4-5CBE-4B9C-A80C-AF66EA588D58 Q53075042-69236BA7-5810-42B3-A20C-FAF1464A98DE

P2860

Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy.

http://www.wikidata.org/entity/Q36462641

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.

@ast

Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.

@en

type

label

Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.

@ast

Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.

@en

prefLabel

Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.

@ast

Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.

@en

P1433

Q36462641-B67F900C-8E34-4061-BB0B-ECDBC361FC62

P1476

Q36462641-E30E2910-2AAF-42D6-929B-99808344964F

P2093

Q36462641-1BCF8A24-35CE-43A6-A80D-3A05271192CE

Q36462641-42C9D353-A81E-4B84-A430-C79E9AF6F7DD

Q36462641-4ABD0A37-C5A1-444B-ACFF-BAB0DD771E9D

Q36462641-C8AB74CC-C3DA-487B-8DC7-1952F2FAF14E

Q36462641-E062E5CD-2C16-4D41-9435-8B774FE7BF77

P2860

Q36462641-42EAD264-AE9C-4E56-9B9D-8409BC279855

Q36462641-51336C22-D5C5-4651-91EE-03891E24A5BD

Q36462641-79F47C20-F9BF-4E77-B83E-21653C779198

Q36462641-82996F67-F77C-4D73-BEA6-8F06F93FF869

Q36462641-98688E18-BF7A-48AD-B163-2349E7882DF1

Q36462641-BD20F8B7-E331-49E8-AE85-FB186A2A3DA2

Q36462641-C873E3EB-18A9-4F5A-B66D-223FEE1DD1AF

Q36462641-E97320B9-0DA3-4510-87B4-C5FA1D235C11

P2888

Q36462641-AA9D427E-AEC2-43A5-ACB0-90D5AB953B5F

P304

Q36462641-8C35442E-885F-4613-8346-E830764A1BD6

P31

Q36462641-B441A471-692D-47DF-A14C-FA05F4273603

P356

Q36462641-C81496FF-8774-4932-A50A-1378A22AAF37

P478

Q36462641-312064B4-977B-46FB-A764-20E708CBD499

P577

Q36462641-339E3EFB-704B-4B70-9D9D-17B5BA5769C1

P5875

Q36462641-10D79DA6-BE6A-4AC1-BA67-7B3E1B6AB55F

P6179

Q36462641-D491FC34-29A5-4A4F-A7E4-EF19A2E9FCC9

P698

Q36462641-36ED8858-46BC-4157-98A8-746788F27B8E

P932

Q36462641-962B299B-096E-4C2D-8DB6-C0E0EED8D063

P356

P1433

Journal of Cardiovascular Magnetic Resonance

P1476

Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.

@en

P2093

Davinder S Jassal

http://www.w3.org/2001/XMLSchema#string

Iain Kirkpatrick

http://www.w3.org/2001/XMLSchema#string

Matthew Lytwyn

http://www.w3.org/2001/XMLSchema#string

Nazanin Fallah-Rad

http://www.w3.org/2001/XMLSchema#string

Tielan Fang

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Assessing the risk of breast cancer.

Noninvasive imaging in myocarditis.

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.

P2888

P304

5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1532-429X-10-5

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5580121

http://www.w3.org/2001/XMLSchema#string

P6179

1019366116

http://www.w3.org/2001/XMLSchema#string

P698

18272009

http://www.w3.org/2001/XMLSchema#string

P932

2244612

http://www.w3.org/2001/XMLSchema#string